Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ken R. Harrap"'
Autor:
Ken R. Harrap, Mark J. McKeage, John Bridgewater, Roger A'Hern, Cyril Fisher, John B. Schofield, Lloyd R. Kelland, Ian Jacobs, Jenny C. Chang, Martin Gore, Bruce A.J. Ponder
Publikováno v:
The Lancet. 343:335-340
Publikováno v:
International journal of cancer. 59(1)
Acquired resistance to tetraplatin [d,1-trans-1,2-diaminocy-clohexane tetrachloroplatinum (IV)] has been generated in vitro in the human ovarian carcinoma cell line PXN94; the derived line, PXN94tetR, was 24-fold resistant to tetraplatin. Intracellul
Publikováno v:
International journal of cancer. 55(5)
Glutathione (GSH) has often been implicated in the mechanism of resistance to platinum anti-cancer drugs. It has been suggested that GSH may reduce the cytotoxicity of these drugs by forming inactive conjugates and by enhancing the repair of DNA-plat
Autor:
Barry A. Murrer, Lloyd R. Kelland, Giandomenico Christen M, Rosanne M. Orr, T. Cobbleigh, Mervyn Jones, Phyllis M. Goddard, Sarah E. Morgan, Ken R. Harrap, Michael J. Abrams
Publikováno v:
Advances in enzyme regulation. 31
In the search for a platinum complex capable of oral administration, the poor bioavailability of established drugs has been circumvented by the discovery of a novel class of platinum (IV) ammine/amine dicarboxylate dichlorides. These compounds, when
Publikováno v:
Biochemical pharmacology. 23(6)
Of 25 compounds tested, eight—namely, 5-azacytidine, gougerotin, cycloheximide, pactamyein, streptovitaein A, adriamyein, daunoruhicin and thioacetamide resulted in the enhancement of liver uridine kinase actiuty in vivo . Puromycin and actinomycin
Publikováno v:
International Journal of Cancer; Oct1994, Vol. 59 Issue 1, p65-70, 6p
Publikováno v:
International Journal of Cancer; Nov1993, Vol. 55 Issue 5, p848-856, 9p